Get the Stockscreener App
1.13
0.00%
0.00
After Hours:
1.16
0.03
+2.65%
Eyenovia Inc stock is traded at $1.13, with a volume of 63,599.
It is up +0.00% in the last 24 hours and up +5.61% over the past month.
Eyenovia Inc is a clinical-stage ophthalmic company developing a pipeline of therapeutics based on its proprietary array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Optejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies that target new indications or new combinations.
See More
Previous Close:
$1.13
Open:
$1.12
24h Volume:
63,599
Relative Volume:
0.30
Market Cap:
$3.20M
Revenue:
$31,800
Net Income/Loss:
$-37.83M
P/E Ratio:
-1.5915
EPS:
-0.71
Net Cash Flow:
$-30.64M
1W Performance:
+4.63%
1M Performance:
+5.61%
6M Performance:
-86.14%
1Y Performance:
-98.28%
1-Day Range:
$1.11
$1.18
1-Week Range:
$1.09
$1.24
52-Week Range:
$0.85
$124.80
Eyenovia Inc Stock (EYEN) Company Profile
Name
Eyenovia Inc
Sector
Industry
Phone
813-766-9539
Address
295 MADISON AVENUE,, NEW YORK, NY
Compare EYEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EYEN
Eyenovia Inc
|
1.13 | 3.06M | 31,800 | -37.83M | -30.64M | -0.71 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Eyenovia Inc Stock (EYEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-01-21 | Initiated | Northland Capital | Outperform |
| Feb-03-20 | Downgrade | Oppenheimer | Outperform → Perform |
Eyenovia Inc Stock (EYEN) Latest News
Eyenovia Delays Q1 2025 10-Q Filing - TipRanks
Eyenovia Faces Nasdaq Delisting Over Equity Shortfall By Investing.com - Investing.com Nigeria
Eyenovia Faces Nasdaq Delisting Over Equity Shortfall - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Eyenovia Inc reports results for the quarter ended December 31Earnings Summary - TradingView
EYENOVIA, INC. SEC 10-K Report - TradingView
Eyenovia Inc expected to post a loss of $7.20 a shareEarnings Preview - TradingView
Eyenovia (EYEN) Advances with Optejet User Filled Device Development | EYEN Stock News - GuruFocus
Eyenovia Provides Development Update on Optejet User Filled Devi - GuruFocus
Eyenovia nears regulatory submission for Optejet UFD device By Investing.com - Investing.com South Africa
Eyenovia Provides Development Update on Optejet User Filled Device (UFD) - The Manila Times
Eyenovia nears regulatory submission for Optejet UFD device - Investing.com
Eyenovia provides development update on Optejet UFD - TipRanks
Revolutionary Eye Drug Device Passes Critical Tests: Eyenovia's Game-Changing Innovation - Stock Titan
Mydriasis Market Predicted to See Upsurge Through 2034, - openPR.com
Mydriasis Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc., Taejoon Pharma - Barchart.com
Eyenovia Delays Yearly Report Filing - TipRanks
Deal Watch: Eyenovia Looks At New Direction In Proposed Merger With Betaliq - insights.citeline.com
Eyenovia falls on plans to seek reverse merger - MSN
Eyenovia Enters Into Non-Binding Letter of Intent to Effect Reverse Merger With Betaliq - VisionMonday.com
Eyenovia And Betaliq Announce Potential Reverse Merger - Nasdaq
Eyenovia Shares Drop 14% Amid Betaliq Merger Talks - Yahoo
Eyenovia stock falls on reverse merger plans (EYEN:NASDAQ) - Seeking Alpha
Eyenovia falls after plans to merge with private firm Betaliq - TradingView
Eyenovia Plans All-Stock Reverse Merger With Betaliq - MarketWatch
Eyenovia and Betaliq Explore Merger to Form New Ophthalmic Company Combining Innovative Drug Delivery Technologies for Glaucoma Treatment - Nasdaq
Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq - GlobeNewswire
Strategic Merger Alert: Eyenovia and Betaliq Join Forces to Revolutionize Eye Care Delivery - StockTitan
EYENOVIA Earnings Preview: Recent $EYEN Insider Trading, Hedge Fund Activity, and More - Nasdaq
Eyenovia, Inc. to Host Earnings Call - ACCESS Newswire
Eyenovia regains compliance with Nasdaq - MSN
Eyenovia, Inc. (NASDAQ:EYEN) Short Interest Up 346.2% in February - The AM Reporter
Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements - GlobeNewswire
Eyenovia Shares Surge After Regaining Nasdaq Compliance: What's Going On? - Benzinga
Eyenovia regains Nasdaq compliance, eyes strategic options By Investing.com - Investing.com Canada
Eyenovia regains Nasdaq compliance, eyes strategic options - Investing.com India
Eyenovia shareholders approve reverse stock split and additional stock reserve - MSN
Eyenovia Escapes Delisting Threat: What's Next for the Optejet Developer? - StockTitan
Eyenovia regains Nasdaq compliance with stock bid price By Investing.com - Investing.com Australia
Eyenovia regains Nasdaq compliance with stock bid price - Investing.com
Eyenovia Inc Stock (EYEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):